A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

Intellia Therapeutics finds itself navigating turbulent waters, with its stock price hitting fresh lows as a combination of clinical setbacks and insider sel ...

After a blistering run, the stock market has lately found itself stuck in a bit of a trading rut, with more and more chatter that the AI boom is ...

The strategic use of certain ETFs can help investors turn unrealized stock-picking losses into tangible tax savings.

Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder ...

Amid a challenging climate for Vancouver’s life sciences sector, Zymeworks Inc. (Nasdaq:ZYME) stands out as a success story ...

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through ...

Wave Life Sciences' shares fell sharply after the clinical-stage biotechnology company priced an upsized $350 million equity raising. The shares were down 10% at $19.09 in early trading Wednesday, ...

Tirupati: The probe into the Tirumala adulterated ghee scandal gained momentum on Monday after Nellore ACB Court handed over two key accused to the CBI Special Investigation Team (SIT) ...

Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week.

Mumbai: A 78-year-old retired government official from Thane lost more than Rs1 crore after falling victim to an online share ...

XOMA Royalty Corporation ('XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully ...